Education and Information to Improve Adherence to Screening for Breast, Colorectal, and Cervical Cancer—Lessons Learned during the COVID-19 Pandemic
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
2.1. Study Design
- We analyzed the data concerning the number of admissions and operations in Italy for patients admitted with oncologic problems during the COVID-19 pandemic (2020 to 2022) and in the pre-pandemic period (2015 to 2019). We selected 14 types of cancer that present the most common indications for surgery in Italy.
- We analyzed the mortality rates in Italy during the pre-pandemic period (2015–2019) and in the pandemic period (2020–2022) related or not to COVID-19 infection.
- A comparison was made between the characteristics (number/adherence) of preventive screening for breast, colorectal, and cervical cancer during the pre-pandemic and the pandemic periods.
2.2. Data Analysis
2.3. Statistical Analysis
3. Results
3.1. Excess Mortality during the Pandemic Period (2020–2022)
3.2. Reduced Number of Hospital Admissions and Surgeries for the 14 Analyzed Types of Cancer
3.3. Heterogeneous Decrease in Surgical Operations
3.3.1. First Year of the Pandemic (2020)
3.3.2. Second and Third Year of the Pandemic (2021–2022)
3.3.3. Adherence to Screening for Breast, Colorectal, and Cervical Cancer
3.3.4. Comparison with Other European Countries
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sterpetti, A.V. Surgical oncology in the pandemic. Lessons learned and future perspectives. Eur. J. Surg. Oncol. 2020, 46, 2162–2163. [Google Scholar] [CrossRef]
- Beatty, J.W.; Clarke, J.M.; Sounderajah, V.; Acharya, A.; Rabinowicz, S.; Martin, G.; Warren, L.R.; Yalamanchili, S.; Scott, A.J.; Burgnon, E.; et al. Impact of the COVID-19 Pandemic on Emergency Adult Surgical Patients and Surgical Services: An International Multi-center Cohort Study and Department Survey. Ann. Surg. 2021, 274, 904–912. [Google Scholar] [CrossRef] [PubMed]
- Berzansky, I.; Reynolds, C.A.; Charlton, B.M. Breast and cervical cancer screenings across gender identity: Results from the Behavioral Risk Factor Surveillance System before and during the COVID-19 pandemic. Cancer Causes Control. 2024, 35, 865–872. [Google Scholar] [CrossRef] [PubMed]
- Schafer, E.J.; Islami, F.; Han, X.; Nogueira, L.M.; Wagle, N.S.; Yabroff, K.R.; Sung, H.; Jemal, A. Changes in cancer incidence rates by stage during the COVID-19 pandemic in the US. Int. J. Cancer 2024, 154, 786–792. [Google Scholar] [CrossRef]
- Negoita, S.; Chen, H.; Sanchez, P.V.; Sherman, R.L.; Henley, S.J.; Siegel, R.L.; Sung, H.; Scott, S.; Benard, V.B.; Kohler, B.A.; et al. Early assessment of the COVID-19 pandemic’s impact on cancer diagnosis. Cancer 2024, 130, 117–127. [Google Scholar] [CrossRef]
- Cardoso, R.; Guo, F.; Heisser, T.; De Schutter, H.; Van Damme, N.; Nilbert, M.C.; Christensen, J.; Bouvier, A.-M.; Bouvier, V.; Launoy, G.; et al. Overall and stage-specific survival of patients with screen-detected colorectal cancer in European countries: A population-based study in 9 countries. Lancet Reg. Health Eur. 2022, 21, 100458. [Google Scholar] [CrossRef]
- Ola, I.; Cardoso, R.; Hoffmeister, M.; Brenner, H. Utilization of colorectal cancer screening tests across European countries: A cross-sectional analysis of the European health interview survey 2018–2020. Lancet Reg. Health Eur. 2024, 41, 100920. [Google Scholar] [CrossRef]
- Brenner, H.; Heisser, T.; Cardoso, R.; Hoffmeister, M. 15-Year Benefits of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality. Ann. Intern. Med. 2023, 176, eL230024. [Google Scholar] [CrossRef]
- Brenner, H.; Heisser, T.; Cardoso, R.; Hoffmeister, M. The underestimated preventive effects of flexible sigmoidoscopy screening: Re-analysis and meta-analysis of randomized trials. Eur. J. Epidemiol. 2024, 39, 743–751. [Google Scholar] [CrossRef]
- Bouvard, V.; Wentzensen, N.; Mackie, A.; Berkhof, J.; Brotherton, J.; Giorgi-Rossi, P.; Kupets, R.; Smith, R.; Arrossi, S.; Bendahhou, K.; et al. The IARC Perspective on Cervical Cancer Screening. N. Engl. J. Med. 2021, 385, 1908–1918. [Google Scholar] [CrossRef] [PubMed]
- Emmons, K.M.; Colditz, G.A. Realizing the Potential of Cancer Prevention—The Role of Implementation Science. N. Engl. J. Med. 2017, 376, 986–990. [Google Scholar] [CrossRef] [PubMed]
- Baglio, G.; Davoli, M.; Seccareccia, F.; Randazzo, M.P.; Carinci, F.; Duranti, G.; Guglielmi, E.; Cuomo, M.; Giordani, B.; Mencancini, C.; et al. Hospital Admissions in Italy AGENAS Ministero Salute DEP Lazio 2022. Available online: https://agenas.gov.it (accessed on 10 December 2023).
- Epicentro ISS. Coronavirus. Istituto Superiore Sanità. 2023. Available online: https://www.epicentro.iss.it (accessed on 6 January 2024).
- European Commission. Database-COVID19-Eurostat-European Commission. 2023. Available online: https://ec.europa.eu (accessed on 10 January 2024).
- Osservatoiro Nazionale Screening. 2021. Available online: https://www.osservatorionazionalescreening.it/ (accessed on 10 January 2024).
- I Numeri del Cancro in Italia. 2021. Available online: https://www.aiom.it/i-numeri-del-cancro-in-italia (accessed on 15 January 2024).
- Mazzoleni, G.; Vittadello, F.; Castellano, I.; Fassan, M.; Serraino, D.; Sapino, A. Analisi delle diagnosi anatomo-patologiche sui tumori operati della mammella e del colon-retto: Confronto 2019 vs 2020. Numeri Cancro in Italia 2022. page 39–44. INTERMEDIA Ed Brescia-Italy. Available online: https://www.aiom.it/2022_AIOM_NDC-web (accessed on 15 January 2024).
- Sterpetti, A.V.; Gabriele, R.; Iannone, I.; Borrelli, V. Underdiagnosed cancer during COVID-19 pandemic and return to normality. Int. J. Cancer 2024, 155, 1139–1140. [Google Scholar] [CrossRef]
- Force, U.P.S.T.; Force, U.P.S.T.; Curry, S.J.; Curry, S.J.; Krist, A.H.; Krist, A.H.; Owens, D.K.; Owens, D.K.; Barry, M.J.; Barry, M.J.; et al. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statemen. JAMA 2018, 320, 674–686. [Google Scholar] [CrossRef]
- Sterpetti, A.V.; Gabriele, R.; Iannone, I.; Sapienza, P.; D’Ermo, G.; Dimarzo, L.; Borrelli, V. Reduced adherence to cervical cancer screening. The importance of information and education for women with low education and low-income. Int. J. Cancer 2024, 155, 776–777. [Google Scholar] [CrossRef]
- Shieh, Y.; Eklund, M.; Sawaya, G.F.; Black, W.C.; Kramer, B.S.; Esserman, L.J. Population-based screening for cancer: Hope and hype. Nat. Rev. Clin. Oncol. 2016, 13, 550–565. [Google Scholar] [CrossRef]
- Lauby-Secretan, B.; Scoccianti, C.; Loomis, D.; Benbrahim-Tallaa, L.; Bouvard, V.; Bianchini, F.; Straif, K. Breast-cancer screening—Viewpoint of the IARC Working Group. N. Engl. J. Med. 2015, 372, 2353–2358. [Google Scholar] [CrossRef]
- Sawaya, G.F.; Smith-McCune, K.; Kuppermann, M. Cervical Cancer Screening: More Choices in 2019. JAMA 2019, 321, 2018–2019. [Google Scholar] [CrossRef]
- Ganguly, A.P.; Baker, K.K.; Redman, M.W.; McClintock, A.H.; Yung, R.L. Racial disparities in the screening mammography continuum within a heterogeneous health care system. Cancer 2023, 129, 3171–3181. [Google Scholar] [CrossRef] [PubMed]
- Dash, C.; Mills, M.G.; Jones, T.D.; Nwabukwu, I.A.; Beale, J.Y.; Hamilton, R.N.; Hurtado-De-Mendoza, A.; O’neill, S.C. Design and pilot implementation of the Achieving Cancer Equity through Identification, Testing, and Screening (ACE-ITS) program in an urban underresourced population. Cancer 2023, 129, 3141–3151. [Google Scholar] [CrossRef]
- Cham, S.; Li, A.; Rauh-Hain, J.A.; Tergas, A.I.; Hershman, D.L.; Wright, J.D.; Melamed, A. Association Between Neighborhood Socioeconomic Inequality and Cervical Cancer Incidence Rates in New York City. JAMA Oncol. 2022, 8, 159–161. [Google Scholar] [CrossRef]
- Kerlikowske, K.; Chen, S.; Bissell, M.C.S.; Lee, C.I.; Tice, J.A.; Sprague, B.L.; Miglioretti, D.L. Population Attributable Risk of Advanced-Stage Breast Cancer by Race and Ethnicity. JAMA Oncol. 2023, e235242. [Google Scholar] [CrossRef] [PubMed]
- Sterpetti, A.V.; Gabriele, R.; Iannone, I.; Dimarzo, L.; Borrelli, V. Disparities in Colorectal Cancer Screening. Ann. Surg. Oncol. 2024, 31, 4560–4562. [Google Scholar] [CrossRef] [PubMed]
- Izzo, P.; Gallo, G.; Codacci Pisanelli, M.; D’Onghia, G.; Macci, L.; Gabriele, R.; Polistena, A.; Izzo, L.; Izzo, S.; Basso, L. Part 2 Vanishing Bile Duct Syndrome in an Adult Patient: Case Report and Review of the Literature. J. Clin. Med. 2022, 11, 3253. [Google Scholar] [CrossRef] [PubMed]
- Sterpetti, A.V.; Gabriele, R.; Iannone, I.; Dimarzo, L.; Borrelli, V. National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough. Cancer 2024, 130, 2395–2397. [Google Scholar] [CrossRef]
- Institute for Health Metrics and Evaluation (IHME). GBD Compare Data Visualization; IHME, University of Washington: Seattle, WA, USA, 2024; Available online: http://vizhub.healthdata.org/gbd-compare (accessed on 10 August 2024).
2015 | 2016 | 2017 | 2018 | 2019 | Pre-Pandemic Mean Annual | 2020 | 2021 | 2022 | Pandemic Mean Annual (% Difference) * | |
---|---|---|---|---|---|---|---|---|---|---|
Esophagus | 795 | 843 | 789 | 831 | 856 | 823 | 827 | 869 | 883 | 860 (+4.5%) |
Stomach | 6746 | 6557 | 6239 | 6146 | 5824 | 6302 | 5088 | 5075 | 4890 | 5018 (−19%) |
Gallbladder | 890 | 917 | 840 | 837 | 771 | 851 | 713 | 731 | 736 | 727 (−9%) |
Liver | 6408 | 6392 | 6303 | 6352 | 6610 | 6413 | 6195 | 5961 | 6126 | 6094 (−7.7%) |
Pancreas | 2626 | 2648 | 2690 | 2809 | 2710 | 2697 | 2778 | 2766 | 2938 | 2827 (+2%) |
Colon | 27,019 | 26,784 | 26,849 | 27,127 | 26,233 | 26,802 | 23,078 | 24,796 | 25,542 | 24,472 (−9.4%) |
Rectum | 7212 | 6844 | 6679 | 6668 | 6051 | 6691 | 5627 | 5615 | 5685 | 5642 (−6.7%) |
Kidney | 10,935 | 11,002 | 11,129 | 11,736 | 11,907 | 11,342 | 10,665 | 11,676 | 12,481 | 11,607 (−3.1%) |
Prostate | 18,952 | 18,972 | 18,673 | 20,270 | 20,688 | 19,511 | 17,115 | 18,645 | 21,324 | 19,028 (−9.4%) |
Bladder | 5294 | 5302 | 5337 | 5201 | 5211 | 5269 | 5241 | 5101 | 5037 | 5126 (−1.4%) |
Breast | 60,630 | 62,172 | 61,797 | 62,738 | 62,343 | 61,936 | 56,057 | 62,764 | 63,986 | 60,935 (−2.5%) |
Lung | 11,454 | 11,590 | 12,039 | 12,458 | 12,782 | 12,065 | 11,637 | 12,083 | 12,808 | 12,176 (−6.4%) |
Uterus | 11,743 | 12,036 | 12,044 | 11,961 | 12,349 | 12,027 | 11,643 | 12,103 | 12,106 | 11,951 (−4.4%) |
Ovary | 4004 | 4042 | 3937 | 3978 | 4058 | 4004 | 3953 | 3909 | 4100 | 3987 (−2.4%) |
TOTAL | 174,708 | 176,101 | 175,345 | 179,112 | 178,393 | 160,617 (−10%) * | 172,094 (−4%) * | 178,642 (−0.5%) * |
2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|
Population of Italian women 50–69 years | 8,695,338 | 8,670,039 | ||
Women 50–59 years | 4,842,322 | 4,803,491 | ||
Women 60–69 years | 3,853,016 | 3,866,548 | ||
Invitations | 3,364,979 | 3,582,635 | 2,593,288 | 3,569,765 |
Attendance (%) | 60.5 | 60.7 | 51.0 | 56.2 |
Number of mammograms | 1,822,8511 | 1,876,721 | 1,242,415 | 1,937,375 |
Benign lesions | 1036 | 952 | 741 | 1343 |
In situ ductal carcinoma | 1069 | 1135 | 801 | 1316 |
Invasive carcinoma | 8045 | 8300 | 6061 | 9845 |
Invasive carcinoma < 1 cm diameter | 2409 | 2455 | 1781 | 2786 |
Total Interviewed Women 28.072 | Attendance to Screening Programs | |
---|---|---|
2017–2019 | 2020–2021 | |
Total 75% | Total 71% | |
AGE 50–59 | 77% | 73% |
AGE 60–69 | 73% | 68% |
Educational level * | ||
1 | 65% | 50% |
2 | 73% | 67% |
3–4 | 78% | 75% |
5–8 | 82% | 80% |
Low income | 60% | 55% |
Middle income | 72% | 65% |
Good income | 81% | 77% |
Italians | 75% | 72% |
Non-Italians ** | 70% | 59% |
Colorectal Cancer Screening—Fecal Occult Blood Test | ||||
---|---|---|---|---|
2018 | 2019 | 2020 | 2021 | |
Italian population 50–69 years of age | 17,123,098 | 17,233,176 | ||
Number invited | 5,939,182 | 5,921,032 | 4,159,765 | 6,416,162 |
Attendance (%) | 42.7% | 40.5% | 34.1% | 38.7% |
Number of tests | 2,570,437 | 2,619,871 | 1,487,636 | 2,607,329 |
% of positive tests | 4.8% | 5.0% | 5.5% | 5.0% |
No. of colonoscopies after positive test | 97,604 | 105,592 | 60,754 | 99,100 |
Diagnoses of carcinoma | 2418 | 2877 | 1402 | 2678 |
Diagnoses of large adenoma | 14,870 | 17,356 | 10,286 | 16,000 |
% of endoscopic resections | 17.9% | 14.6% | 19.3% | 18.2% |
Subgroups with Statistical Significance at Univariate Analysis | % of Interviewed Persons Who Had Timely Screening | Inside the National Organized Screening Program | Outside the National Organized Screening Program |
---|---|---|---|
47% | 39% | 8% | |
Sex | |||
Males | 48% | 39% | 8% |
Females | 46% | 39% | 7% |
Age | |||
50–59 | 42% | 34% | 7% |
60–69 | 52% | 44% | 8% |
Education | |||
1 | 37% | 31% | 6% |
2 | 45% | 39% | 6% |
3–4 | 49% | 41% | 8% |
5–8 | 50% | 38% | 12% |
Family income | |||
Low | 32% | 26% | 6% |
Middle | 41% | 34% | 7% |
High | 54% | 46% | 8% |
Citizenship | |||
Italian | 47% | 39% | 8% |
Immigrants (low-income countries) | 43% | 39% | 4% |
Screening Test | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|
No. of Italian Women Aged 25–64 Years | 16,183,088 | 16,190,022 | 16,191,04 | 16,232,654 |
Overall invited women for screening | 3,966,409 | 3,835,318 | 2,598,295 | 3,426,660 |
Adherence to invitation (%) | 41.7 | 40.7 | 34.2 | 39.2 |
Cytology | 2,453,583 | 2,212,192 | 1,223,873 | 1,434,395 |
Adherence to invitation (%) | 34.2 | 33.7 | 27.5 | 34.8 |
Diagnoses of CIN2+ for every 1000 examined women | 4.6 | 5.0 | 5.5 | 4.5 |
HPV Test + Cytology | 1,480,776 | 1,632,362 | 1,360,553 | NA |
Adherence to invitation (%) | 48.5 | 45.2 | 37.6 | NA |
Diagnoses of CIN2+ for every 1000 examined women | 5.6 | 6.4 | 6.8 | NA |
Number of total diagnoses for CIN2+ | 7.177 | 7.625 | 5.228 | NA |
Subgroups with Statistical Significance at Univariate Analysis | % of Women Who Had Timely Screening | Inside the National Organized Screening Program | Outside the National Organized Screening Program |
---|---|---|---|
79% | 49% | 30% | |
Age | |||
25–34 | 74% | 42% | 32% |
35–49 | 83% | 47% | 36% |
50–64 | 78% | 53% | 25% |
Education | |||
1 | 60% | 43% | 17% |
2 | 74% | 51% | 23% |
3–4 | 81% | 52% | 31% |
5–8 | 84% | 47% | 37% |
Family Income | |||
Low | 67% | 44% | 23% |
Middle | 77% | 48% | 29% |
High | 84% | 52% | 32% |
Citizenship | |||
Italian | 79% | 48% | 31% |
Immigrants (low-income countries) | 74% | 55% | 19% |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gabriele, R.; Campagnol, M.; Sapienza, P.; Borrelli, V.; Di Marzo, L.; Sterpetti, A.V. Education and Information to Improve Adherence to Screening for Breast, Colorectal, and Cervical Cancer—Lessons Learned during the COVID-19 Pandemic. Cancers 2024, 16, 3042. https://doi.org/10.3390/cancers16173042
Gabriele R, Campagnol M, Sapienza P, Borrelli V, Di Marzo L, Sterpetti AV. Education and Information to Improve Adherence to Screening for Breast, Colorectal, and Cervical Cancer—Lessons Learned during the COVID-19 Pandemic. Cancers. 2024; 16(17):3042. https://doi.org/10.3390/cancers16173042
Chicago/Turabian StyleGabriele, Raimondo, Monica Campagnol, Paolo Sapienza, Valeria Borrelli, Luca Di Marzo, and Antonio V. Sterpetti. 2024. "Education and Information to Improve Adherence to Screening for Breast, Colorectal, and Cervical Cancer—Lessons Learned during the COVID-19 Pandemic" Cancers 16, no. 17: 3042. https://doi.org/10.3390/cancers16173042
APA StyleGabriele, R., Campagnol, M., Sapienza, P., Borrelli, V., Di Marzo, L., & Sterpetti, A. V. (2024). Education and Information to Improve Adherence to Screening for Breast, Colorectal, and Cervical Cancer—Lessons Learned during the COVID-19 Pandemic. Cancers, 16(17), 3042. https://doi.org/10.3390/cancers16173042